NEW YORK (GenomeWeb News) — Diamics will supply its molecular-based cancer-diagnostics systems and cervical cancer tools to a Beijing hospital for three years in exchange for at least $22 million, the company said today.
 
Diamics’ C-Map cervical cancer screening system, which is in clinical trials in the US, uses antibodies to identify cell colonies showing dysregulated growth, which could help identify cervical lesions. 
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

CNBC reports that Amazon invested in the startup Grail as it sees an opportunity for its cloud computing company in genomics.

Lawrence Krauss writes at Slate that science is needed for good public policy and should not be ignored.

Researchers are working on re-making the yeast genome from scratch, according to the Associated Press.

In Cell this week: functional profiling of Plasmodium genome, a self-inactivating rabies virus, and more.